Global Uterine Cancer Therapeutics & Diagnostics Market to grow with a CAGR of 5.80%.
Increasing
healthcare infrastructure and a supportive regulatory environment are the major
drivers for the Global Uterine Cancer Therapeutics & Diagnostics Market.
According
to TechSci Research report, “Global Uterine Cancer Therapeutics &
Diagnostics Market Industry Size, Share, Trends, Competition, Opportunity and
Forecast, 2018-2028”, Global
Uterine Cancer Therapeutics & Diagnostics Market has valued at USD 20.50
billion in 2022 and is anticipated to witness an impressive growth in the
forecast period with a CAGR of 5.80% through 2028. This can be due to
collaborations and partnerships among leading companies with a diverse approach
to merge the expertise of individual companies and to strengthen their position
in the market. Treatment
innovations are a significant driver in the Global Uterine Cancer Therapeutics
& Diagnostics Market. Minimally invasive surgical techniques, such as
laparoscopy and robotic-assisted surgery, have become more widely used in the
treatment of uterine cancer. These approaches offer smaller incisions, reduced
blood loss, faster recovery times, and shorter hospital stays compared to
traditional open surgery. Sentinel lymph node mapping is a technique used
during surgery to identify and selectively remove lymph nodes most likely to
contain cancer cells. This reduces the need for extensive lymph node dissection
and lowers the risk of complications. Hyperthermic Intraperitoneal Chemotherapy
(HIPEC) is an innovative treatment that involves delivering heated chemotherapy
directly to the abdominal cavity during surgery. This approach aims to
eliminate residual cancer cells and improve treatment outcomes.
Browse
over XX market data Figures and spread through 110
Pages and an in-depth TOC on " Global Uterine Cancer Therapeutics & Diagnostics Market.”
Uterine
cancer therapeutics and diagnostics refer to the medical strategies,
treatments, and tools used to manage and treat uterine cancer, as well as the
methods for diagnosing and monitoring the disease. Uterine cancer, also known
as endometrial cancer, is a type of cancer that originates in the lining of the
uterus, called the endometrium. In
April 2021, The VENTANA MMR RxDx Panel for patients with advanced or recurrent
endometrial cancer was approved by the U.S. Food and Drug Administration (FDA),
according to a Roche announcement. MMR is a biochemical system that works to
fix some mistakes that can happen accidentally while replicating DNA. Testing
can help find patients who qualify for treatment with JEMPERLI monotherapy, a
GlaxoSmithKline (GSK) anti-PD1 immunotherapy that has received FDA approval.
The most typical case of MMR deficiency is endometrial cancer. With the use of
an extensive panel of DNA mismatch repair (MMR) biomarkers examined by
immunohistochemistry (IHC), this companion diagnostic (CDx) offers clinicians a
standardized testing alternative. The VENTANA MMR RxDx Panel was given FDA
approval, giving clinicians access to a fully automated, simple-to-use MMR test
to determine which patients qualify for treatment with JEMPERLI.
Immunotherapy resistance is a significant
challenge in the global uterine cancer therapeutics and diagnostics market, as
it is in the broader field of cancer treatment. Immunotherapy has shown promise
in the treatment of various cancers, including uterine cancer, by harnessing
the patient's immune system to target and destroy cancer cells. However, not
all patients respond to immunotherapy, and some may develop resistance to these
treatments. Uterine cancer, like many other cancers, can be
heterogeneous, meaning that different regions of the tumour may have varying
genetic characteristics. Some tumour cells may not express the target antigens
recognized by immunotherapy drugs, rendering the treatment ineffective in those
areas. Tumours can
create a suppressive microenvironment that inhibits the activity of immune
cells. Immune checkpoint proteins, such as PD-1 and PD-L1, can be upregulated
in the tumour microenvironment, leading to immune evasion. This immune
suppression can limit the effectiveness of immunotherapies.
Global Uterine Cancer Therapeutics &
Diagnostics Market segmentation is based on cancer type, therapeutics, diagnostics,
and Region. Based on cancer type, Global Uterine Cancer
Therapeutics & Diagnostics Market is segmented into Endometrial Adenocarcinoma,
Adenosquamous Carcinoma, Papillary Serous Carcinoma, Uterine Sarcoma. Adenosquamous carcinoma is a type of cancer
that exhibits both glandular (adenocarcinoma) and squamous (squamous cell
carcinoma) characteristics. It is a relatively rare and aggressive form of
cancer that can occur in various organs throughout the body, but it is mostly
associated with the respiratory and gastrointestinal tracts. Adenosquamous carcinoma can originate from
different organs, but it is most found in the lungs, esophagus, and cervix. In
the lungs, it is often associated with a history of smoking. Adenosquamous carcinoma is considered
aggressive because it often exhibits characteristics of both adenocarcinoma and
squamous cell carcinoma, which can make it challenging to treat. It tends to be
more aggressive than pure adenocarcinoma or squamous cell carcinoma. Diagnosis of adenosquamous carcinoma
typically involves a biopsy of the affected tissue. Pathologists examine the
tissue under a microscope to identify the presence of both glandular and
squamous components. Treatment
approaches for adenosquamous carcinoma may involve a combination of surgery,
radiation therapy, and chemotherapy.
Based on Region, North America dominated the Global Uterine Cancer
Therapeutics & Diagnostics Market. The region has well-established
cancer awareness and screening programs that encourage early detection. Routine
screenings and public health campaigns contribute to higher uterine cancer
diagnosis rates. Most North American countries, including the United States and
Canada, have health insurance systems that provide coverage for cancer
treatments. This financial support enables patients to access costly treatments
and diagnostics. The aging population in North America contributes to a higher
incidence of uterine cancer. Older individuals are more prone to developing
this type of cancer, and the region's demographic trends play a role in its
prominence. The competitive nature of the healthcare industry in North America
fosters innovation and the rapid adoption of new technologies and treatments.
Asia-pacific region to fastest growth in the Global Uterine
Cancer Therapeutics & Diagnostics Market. Uterine cancer incidence rates
have been increasing in many countries across the Asia-Pacific region. Factors
contributing to this rise include changes in lifestyle, increasing obesity
rates, and aging populations. Efforts to raise awareness about uterine cancer
and the importance of early detection have been on the rise. Greater awareness
leads to more women seeking medical attention and undergoing screening, which
can result in earlier diagnosis and treatment. Many countries in the
Asia-Pacific region have been investing in healthcare infrastructure and
facilities. Improved access to medical services and better diagnostic
capabilities contribute to early detection and treatment.
Some of the major companies
operating in the Global Uterine Cancer
Therapeutics & Diagnostics Market include:
- Ariad Pharmaceuticals, Inc.
- Abbott Laboratories Inc.
- Becton, Dickinson & Co.
- GlaxoSmithKline Plc
- Merck & Co., Inc.
- Novartis AG
- Sanofi SA
- Siemens Healthcare Inc.
- Roche
Holding AG
Download Free Sample Report
Customers can also request 10% free customization on this report.
“Certain areas, particularly in North America, are
projected to exert significant demand of uterine cancer therapies. The growth
in the competitive landscape and the presence of well-established companies in
the market, committed to enhance the overall wellbeing of people each year, are
expected to contribute to a remarkable growth of the Global Uterine Cancer
Therapeutics & Diagnostics Market in the forecast period," said Mr.
Karan Chechi, Research Director with TechSci Research, a research-based Global
management consulting firm.
Uterine Cancer Therapeutics &
Diagnostics Market – Global Industry Size, Share, Trends, Opportunity, and
Forecast, 2018-2028 Segmented by Cancer
Type (Endometrial Adenocarcinoma, Adenosquamous Carcinoma, Papillary Serous
Carcinoma, Uterine Sarcoma), by Therapeutics (Surgery, Immunotherapy, Radiation
Therapy, Chemotherapy, others), by Diagnostics (Biopsy, Pelvic Ultrasound,
Hysteroscopy, Dilation and Curettage, CT scan), By Region, and Competition evaluated the future growth potential of
Global Uterine Cancer Therapeutics & Diagnostics Market and provides
statistics & information on market size, structure, and future market
growth. The report intends to provide innovative market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Uterine Cancer Therapeutics &
Diagnostics Market.
Contact
Mr. Ken
Mathews
708 Third
Avenue,
Manhattan, NY,
New York –
10017
Tel:
+1-646-360-1656
Email: [email protected]
Website: www.techsciresearch.com